FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136536672> ?p ?o ?g. }

• W2136536672 endingPage "5125" @default.
• W2136536672 startingPage "5117" @default.
• W2136536672 abstract "To assess the validity of objective response to chemotherapy as a surrogate end point for survival in metastatic breast cancer.We carried out a meta-analysis on individual data from 2,126 metastatic breast cancer patients who were enrolled onto 10 randomized trials comparing standard versus intensified epirubicin-containing chemotherapy.The intensified chemotherapy was associated with a significantly higher tumor response rate compared with standard chemotherapy (pooled odds ratio for nonresponse, 0.60; 95% CI, 0.51 to 0.72). The intensified regimens also led to better (although not significant) survival (pooled odds ratio, 0.94; 95% CI, 0.86 to 1.04; P = .22). Tumor response was a highly significant predictor of survival (P < .0001). When tumor response was introduced in the Cox model, the hazard ratio in favor of experimental treatment changed from 0.94 to 1.005 (95% CI, 0.91 to 1.11; P = .92), indicating that no residual effect of the experimental treatment on survival was present once tumor response was adjusted for. This suggests that the overall survival benefit of intensified epirubicin was a result of the increase in response rate. The median survival time of patients with complete response and partial response was 28.8 months (95% CI, 25.4 to 45.3 months) and 21.3 months (95% CI, 19.2 to 22.4 months), respectively; whereas, the median survival time of patients with no response was 14.6 months (95% CI, 13.9 to 15.4 months).These results support the hypothesis that the achievement of an objective response to chemotherapy in metastatic breast cancer is associated with a true survival benefit. The potential role of objective response as a surrogate end point for survival in chemotherapy trials of metastatic breast cancer warrants further investigation." @default.
• W2136536672 created "2016-06-24" @default.
• W2136536672 creator A5026665975 @default.
• W2136536672 creator A5031754069 @default.
• W2136536672 creator A5034457278 @default.
• W2136536672 creator A5040000378 @default.
• W2136536672 creator A5041125823 @default.
• W2136536672 creator A5041575636 @default.
• W2136536672 creator A5057277696 @default.
• W2136536672 creator A5062442517 @default.
• W2136536672 creator A5074479074 @default.
• W2136536672 creator A5089288192 @default.
• W2136536672 date "2005-08-01" @default.
• W2136536672 modified "2023-09-25" @default.
• W2136536672 title "Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients" @default.
• W2136536672 cites W1898988182 @default.
• W2136536672 cites W1900639705 @default.
• W2136536672 cites W1946018534 @default.
• W2136536672 cites W1963731721 @default.
• W2136536672 cites W1969729309 @default.
• W2136536672 cites W1976476604 @default.
• W2136536672 cites W2007753377 @default.
• W2136536672 cites W2011453559 @default.
• W2136536672 cites W2011945829 @default.
• W2136536672 cites W2022579397 @default.
• W2136536672 cites W2076545717 @default.
• W2136536672 cites W2080675410 @default.
• W2136536672 cites W2110608811 @default.
• W2136536672 cites W2116290933 @default.
• W2136536672 cites W2116356654 @default.
• W2136536672 cites W2124589535 @default.
• W2136536672 cites W2126133903 @default.
• W2136536672 cites W2150981991 @default.
• W2136536672 cites W2155949904 @default.
• W2136536672 cites W2164409215 @default.
• W2136536672 cites W2169073956 @default.
• W2136536672 cites W2176579253 @default.
• W2136536672 cites W2182813864 @default.
• W2136536672 cites W2185154108 @default.
• W2136536672 cites W2270235662 @default.
• W2136536672 cites W2340435826 @default.
• W2136536672 cites W4239330499 @default.
• W2136536672 cites W4241240326 @default.
• W2136536672 cites W4246318045 @default.
• W2136536672 doi "https://doi.org/10.1200/jco.2005.02.106" @default.
• W2136536672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15955906" @default.
• W2136536672 hasPublicationYear "2005" @default.
• W2136536672 type Work @default.
• W2136536672 sameAs 2136536672 @default.
• W2136536672 citedByCount "115" @default.
• W2136536672 countsByYear W21365366722012 @default.
• W2136536672 countsByYear W21365366722013 @default.
• W2136536672 countsByYear W21365366722014 @default.
• W2136536672 countsByYear W21365366722015 @default.
• W2136536672 countsByYear W21365366722016 @default.
• W2136536672 countsByYear W21365366722017 @default.
• W2136536672 countsByYear W21365366722018 @default.
• W2136536672 countsByYear W21365366722019 @default.
• W2136536672 countsByYear W21365366722020 @default.
• W2136536672 countsByYear W21365366722021 @default.
• W2136536672 countsByYear W21365366722023 @default.
• W2136536672 crossrefType "journal-article" @default.
• W2136536672 hasAuthorship W2136536672A5026665975 @default.
• W2136536672 hasAuthorship W2136536672A5031754069 @default.
• W2136536672 hasAuthorship W2136536672A5034457278 @default.
• W2136536672 hasAuthorship W2136536672A5040000378 @default.
• W2136536672 hasAuthorship W2136536672A5041125823 @default.
• W2136536672 hasAuthorship W2136536672A5041575636 @default.
• W2136536672 hasAuthorship W2136536672A5057277696 @default.
• W2136536672 hasAuthorship W2136536672A5062442517 @default.
• W2136536672 hasAuthorship W2136536672A5074479074 @default.
• W2136536672 hasAuthorship W2136536672A5089288192 @default.
• W2136536672 hasBestOaLocation W21365366721 @default.
• W2136536672 hasConcept C121608353 @default.
• W2136536672 hasConcept C126322002 @default.
• W2136536672 hasConcept C141071460 @default.
• W2136536672 hasConcept C141341695 @default.
• W2136536672 hasConcept C143998085 @default.
• W2136536672 hasConcept C156957248 @default.
• W2136536672 hasConcept C207103383 @default.
• W2136536672 hasConcept C2775930923 @default.
• W2136536672 hasConcept C2776694085 @default.
• W2136536672 hasConcept C2780835546 @default.
• W2136536672 hasConcept C44249647 @default.
• W2136536672 hasConcept C50382708 @default.
• W2136536672 hasConcept C530470458 @default.
• W2136536672 hasConcept C71924100 @default.
• W2136536672 hasConceptScore W2136536672C121608353 @default.
• W2136536672 hasConceptScore W2136536672C126322002 @default.
• W2136536672 hasConceptScore W2136536672C141071460 @default.
• W2136536672 hasConceptScore W2136536672C141341695 @default.
• W2136536672 hasConceptScore W2136536672C143998085 @default.
• W2136536672 hasConceptScore W2136536672C156957248 @default.
• W2136536672 hasConceptScore W2136536672C207103383 @default.
• W2136536672 hasConceptScore W2136536672C2775930923 @default.
• W2136536672 hasConceptScore W2136536672C2776694085 @default.
• W2136536672 hasConceptScore W2136536672C2780835546 @default.
• W2136536672 hasConceptScore W2136536672C44249647 @default.

• next